Rhinosinusitis

touchRESPIRATORY were delighted to catch up with Prof Peter Hellings (Catholic University of Leuven; University Hospitals of Leuven, Leuven, Belgium) to discuss this year’s EUFOREA global CRSwNP awareness day that took place on 20 April 2022 and the importance of physician and patient awareness for improved patient outcomes. Questions Can you highlight the burden of […]

Watch ENT specialists discuss key considerations in optimizing the management of patients with CRSwNP.

Aspirin-exacerbated respiratory disease (AERD) is a clinical triad of asthma, nasal polyposis and sensitivity to aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs). These patients have severe sinopulmonary inflammation, often refractory to standard treatments.1 However, significant advances in the management of both asthma and nasal polyposis allow for new treatment options and management algorithms. This article aims […]

Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory disease of the nose and paranasal sinuses that is prevalent worldwide, affecting 10–12% of adults.1,2 It is phenotypically classified by the presence or absence of nasal polyps. Chronic rhinosinusitis with nasal polyposis (CRSwNP) is estimated to affect up to 4% of the population, and consists of multiple endotypes that […]

Watch a panel of experts discuss challenges in the diagnosis of CRSwNP and considerations for optimal management of the disease.

Dr Stella Lee (University of Pittsburgh, Pittsburgh, PA, US) spoke with touchRESPIRATORY around the SYNAPSE study, which investigated the efficacy and safety of mepolizumab in patients with chronic rhinosinusitis with nasal polyps (Clinical Trial Identifier: NCT03085797). The abstract ‘Mepolizumab Improves Health Related Quality of Life for Patients with Chronic Rhinosinusitis with Nasal Polyps: Data from […]

We were delighted to talk to Dr Stella Lee (University of Pittsburgh, Pittsburgh, PA, US) around the current and future treatment options for chronic rhinosinusitis with nasal polyps. Questions What is the impact of chronic rhinosinusitis with nasal polyps on quality of life, and what are the limitations of current therapies? (0:18) What biologics are […]

It was a pleasure to speak with Professor Whitney Stevens (Northwestern University Feinberg School of Medicine, Chicago, IL, US) around aspirin desensitisation in aspirin-exacerbated respiratory disease. ‘Aspirin desensitization for AERD in 2020: An update from the AERD work group.’ was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March […]

Chronic rhinosinusitis (CRS) is a clinical syndrome defined by symptomatic inflammation of the paranasal sinuses and nasal cavity for at least 12 weeks in duration. Historically, CRS has been classified into 2 subgroups, CRS with nasal polyps (CRSwNP) and CRS without nasal polyps. Those with CRSwNP have a more significant burden of disease and poor […]